Patents by Inventor Jan E. de Vries

Jan E. de Vries has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMAN MONOCLONAL ANTIBODIES AGAINST HUMAN IL-4
    Publication number: 20100254993
    Abstract: Antibodies which are specific for human interleukin-4 and their use in the treatment of IL-4 and/or IgE mediated diseases.
    Type: Application
    Filed: April 15, 2010
    Publication date: October 7, 2010
    Inventors: JOSÉ M. CARBALLIDO HERRERA, JAN E. DE VRIES, CHRISTOPH SCHWAERZLER
  • Induction of Tolerogenic Phenotype in Mature Dendritic Cells
    Publication number: 20100183602
    Abstract: The present invention relates to the use of a CD45 binding molecule to modulate the function of Dendritic cells. In particular the present invention relates to the use of a CD45 binding molecule to induce tolerogenic dendritic cells, useful in the treatment of diseases or disorders such as autoimmune diseases, transplant rejection.
    Type: Application
    Filed: June 3, 2008
    Publication date: July 22, 2010
    Inventors: Jose M. Carballido Herrera, Jan E. De Vries, Ulf Korthaeuer, Maria Grazia Roncarolo, Silvia Adriana Gregori
  • Human monoclonal antibodies against human IL-4
    Patent number: 7740843
    Abstract: Antibodies which are specific for human interleukin-4 and their use in the treatment of IL-4 and/or IgE mediated diseases.
    Type: Grant
    Filed: August 2, 2005
    Date of Patent: June 22, 2010
    Assignee: Novartis AG
    Inventors: José M. Carballido Herrera, Jan E. De Vries, Christoph Schwaerzler
  • Human Monoclonal Antibodies Against Human IL-4
    Publication number: 20080241160
    Abstract: Antibodies which are specific for human interleukin-4 and their use in the treatment of IL-4 and/or IgE mediated diseases.
    Type: Application
    Filed: August 2, 2005
    Publication date: October 2, 2008
    Inventors: José M. Carballido Herrera, Jan E. De Vries, Christoph Schwaerzler
  • Methods for modulating antigen-specific immune responses
    Patent number: 6884410
    Abstract: Interleukin-10 for producing a population of cells which are capable of inhibiting or suppressing reactions to alloantigens, for example in graft-versus-host disease or tissue rejection, is described. Interleukin-10 for reducing responses in mixed lymphocyte response (MLR) is also described. Exogenous or induced endogenous IL-10 may be used for the inhibition or suppression of the reactions to alloantigens.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: April 26, 2005
    Assignee: Schering Corporation
    Inventors: Maria-Grazia Roncarolo, Rene de Waal Malefyt, Rosa Bacchetta, Herve M. Groux, Jan E. de Vries
  • Methods for modulating SLAM-expressing T cells
    Patent number: 6399065
    Abstract: Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: June 23, 1997
    Date of Patent: June 4, 2002
    Assignee: Schering Corporation
    Inventors: Gregorio Aversa, Chia-Chun J. Chang, Benjamin G. Cocks, Jan E. de Vries
  • Purified genes encoding mammalian cell surface antigens; proteins and antibodies
    Patent number: 6372899
    Abstract: Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said antigen. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: November 25, 1998
    Date of Patent: April 16, 2002
    Assignee: Schering Corporation
    Inventors: Gregorio Aversa, Chia-Chun J. Chang, Benjamin G. Cocks, Jan E. de Vries
  • Treatment of neoplastic disease with interleukin-10
    Patent number: 6319493
    Abstract: A method is provided for treating tumors, e.g., lymphocytic leukemias, which comprises administering to a mammal an effective amount of interleukin-10.
    Type: Grant
    Filed: April 19, 2000
    Date of Patent: November 20, 2001
    Assignee: Schering Corporation
    Inventors: Paulo J. Vieira, Kevin W. Moore, Rene de Waal Malefyt, Jan E. de Vries, Anne-Catherine Fluckiger, Jacques Banchereau
  • Use of interleukin-10 to produce a population of suppressor cells
    Patent number: 6277635
    Abstract: Interleukin-10 for producing a population of cells which are capable of inhibiting or suppressing reactions to alloantigens, for example in graft-versus-host disease or tissue rejection, is described. Interleukin-10 for reducing responses in mixed lymphocyte response (MLR) is also described. Exogenous or induced endogenous IL-10 may be used for the inhibition or suppression of the reactions to alloantigens.
    Type: Grant
    Filed: May 6, 1996
    Date of Patent: August 21, 2001
    Assignee: Schering Corporation
    Inventors: Maria-Grazia Roncarolo, Rene de Waal Malefyt, Rosa Bacchetta, Herve M. Groux, Jan E. de Vries
  • Materials and methods for screening human interleukin-4 antagonists/agonists
    Patent number: 6200805
    Abstract: Stably-transformed human cell lines containing a reporter gene operatively linked to an IL-4-responsive element are provided. In some embodiments a human Fc&egr;RII IL-4-responsive element is used. In other embodiments a human germline &egr; transcript promoter is used as the responsive element. Also provided are methods for using such transformed cell lines to screen for agonists and/or antagonists of human interleukin-4.
    Type: Grant
    Filed: May 28, 1993
    Date of Patent: March 13, 2001
    Assignee: Schering Corporation
    Inventors: Jan E. de Vries, Chung-Her Jenh, Satwant K. Narula, Paul J. Zavodny
  • Treatment of neoplastic disease with interleukin-10
    Patent number: 6106823
    Abstract: A method is provided for treating tumors, e.g., lymphocytic leukemias, which comprises administering to a mammal an effective amount of interleukin-10.
    Type: Grant
    Filed: December 17, 1993
    Date of Patent: August 22, 2000
    Assignee: Schering Corporation
    Inventors: Paulo J. Vieira, Kevin W. Moore, Rene de Waal Malefyt, Jan E. de Vries, Anne-Catherine Fluckiger, Jacques Banchereau
  • Mammalian cell surface antigens
    Patent number: 5977303
    Abstract: Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said antigen. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 2, 1999
    Assignee: Schering Corporation
    Inventors: Gregorio Aversa, Chia-Chun J. Chang, Benjamin G. Cocks, Jan E. de Vries
  • Human interleukin-4 antagonist/agonist screens
    Patent number: 5958707
    Abstract: Stably-transformed human cell lines containing a reporter gene operatively linked to an IL-4-responsive element are provided. In some embodiments a human Fc.sub..epsilon. RII IL-4-responsive element is used. In other embodiments a human germline .epsilon. transcript promoter is used as the responsive element. Also provided are methods for using such transformed cell lines to screen for agonists and/or antagonists of human interleukin-4.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: September 28, 1999
    Assignee: Schering Corporation
    Inventors: Jan E. de Vries, Chung-Her Jenh, Satwant K. Narula, Paul J. Zavodny
  • Antibodies to the slam protein expressed on activated T cells
    Patent number: 5576423
    Abstract: Purified genes which encode a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said antigen. Methods of using said reagents and diagnostic kits are also provided.
    Type: Grant
    Filed: December 2, 1994
    Date of Patent: November 19, 1996
    Assignee: Schering Corporation
    Inventors: Gregorio Aversa, Chia-Chun J. Chang, Benjamin G. Cocks, Jan E. de Vries